Russell D. Cohen to Remission Induction
This is a "connection" page, showing publications Russell D. Cohen has written about Remission Induction.
Connection Strength
1.437
-
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007 Nov 01; 26(9):1179-86.
Score: 0.272
-
Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis. 2015 Jul; 21(7):1719-36.
Score: 0.116
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
Score: 0.110
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.086
-
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Drug Des Devel Ther. 2011 Feb 27; 5:111-6.
Score: 0.086
-
What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S236-7.
Score: 0.072
-
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct; 12(10):979-94.
Score: 0.063
-
Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep. 2004 Dec; 6(6):488-95.
Score: 0.056
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.052
-
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
Score: 0.049
-
Methotrexate in IBD--move over 6-MP? Not so fast... Gastroenterology. 2002 Nov; 123(5):1737-9.
Score: 0.048
-
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
Score: 0.043
-
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
Score: 0.040
-
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
Score: 0.040
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.038
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.037
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
Score: 0.036
-
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
Score: 0.035
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.035
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.035
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
Score: 0.033
-
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
Score: 0.026
-
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006 Oct; 12(10):972-8.
Score: 0.016
-
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
Score: 0.014